All In Biotech

NDA 214121 · Accord Hlthcare

Methotrexate

Methotrexate · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 24, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,088

570 Phase 3, 212 recruiting

FAERS reports

487,627

358,960 serious, 38,300 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 10, 2022 Supplement 1 · Efficacy LetterLabel
  • Aug 24, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LetterReview
1 products under this application
  • METHOTREXATE · METHOTREXATE 5GM/50ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,088 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective93,085
  • rheumatoid arthritis42,801
  • arthralgia40,718
  • off label use40,573
  • pain39,635
  • fatigue33,027
  • nausea28,920
  • joint swelling24,995
  • drug intolerance24,515
  • condition aggravated23,993
  • headache23,450
  • rash22,590

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,891
20055,584
20065,149
20078,029
20089,257
20099,418
20109,834
201110,985
201215,617
201317,734
201417,445
201521,279
201625,472
201732,187
201843,779
201940,975
202046,026
202130,926
202234,807
202332,370
202427,844
202523,597
202613,413

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Methotrexate* (Methotrexate Sodium)

2024 spending

$57.2M

Beneficiaries

551,528

2,414,242 claims

Per beneficiary

$104

$0.63 per unit

View as table
YearSpending
2020$108,638,057
2021$98,497,524
2022$88,037,997
2023$81,914,088
2024$57,213,221

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Accord Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.